Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

EUROFINS SCIENT. And BIOMERIEUX Have A High Dividend Yield And Return On Equity In The Diagnostics & Research Industry.

Loading stream...

(vianews) - eurofins scient. (erf.pa) is among this list of stock assets with the highest dividend rate and return on equity on the diagnostics & research industry.

financial asset price forward dividend yield return on equity
eurofins scient. (erf.pa) €56.30 1.83% 9.12%
biomerieux (bim.pa) €96.42 0.92% 9.87%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. eurofins scient. (erf.pa)

1.83% forward dividend yield and 9.12% return on equity

eurofins scientific se, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. the company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. it provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. in addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, gmo, grain, meat, nano material, pesticides, and residual dna testing. further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. additionally, the company provides forensic, genomic, maritime, materials and engineering, reach, and technologies services. the company was founded in 1987 and is headquartered in luxembourg city, luxembourg.

earnings per share

as for profitability, eurofins scient. has a trailing twelve months eps of €2.28.

pe ratio

eurofins scient. has a trailing twelve months price to earnings ratio of 24.69. meaning, the purchaser of the share is investing €24.69 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.12%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jul 4, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1.83%.

more news about eurofins scient..

2. biomerieux (bim.pa)

0.92% forward dividend yield and 9.87% return on equity

biomérieux s.a. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the americas, europe, the middle east, africa, and the asia pacific. the company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. it also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the biomérieux vision suite name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. the company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. biomérieux s.a. was formerly known as b-d mérieux. the company was founded in 1963 and is headquartered in marcy l'etoile, france. biomérieux s.a. is a subsidiary of institut mérieux sa.

earnings per share

as for profitability, biomerieux has a trailing twelve months eps of €3.82.

pe ratio

biomerieux has a trailing twelve months price to earnings ratio of 25.24. meaning, the purchaser of the share is investing €25.24 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.87%.

more news about biomerieux.